Evidence map›Paper›PMID 32027938›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2020

Advances and limitations of drug delivery systems formulated as eye drops.

Clotilde Jumelle, Shima Gholizadeh, Nasim Annabi, Reza Dana

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
153citing papers in PubMed, 3 pooled it
14.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

153 citing papers in PubMed, 3 syntheses or guidelines pooled it, 371 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

93 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Clotilde JumelleSchepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.
Shima GholizadehChemical and Biomolecular Engineering, University of California - Los Angeles, Los Angeles, CA, USA.
Nasim AnnabiChemical and Biomolecular Engineering, University of California - Los Angeles, Los Angeles, CA, USA; Center for Minimally Invasive Therapeutics (C-MIT), California NanoSystems Institute (CNSI), University of California - Los Angeles, Los Angeles, CA, USA. Electronic address: nannabi@ucla.edu.
Reza DanaSchepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA. Electronic address: reza_dana@meei.harvard.edu.
Massachusetts Eye and Ear Infirmary · USCalifornia NanoSystems Institute · USUniversity of California, Los Angeles · US

Funding

Engineering highly elastic surgical sealants with hemostatic propertiesR01HL140618 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANNABI, NASIM, KHADEMHOSSEINI, ALI · 2018 to 2021
$2.8M
Engineering a naturally derived and highly adhesive surgical sealantR01EB023052 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANNABI, NASIM, KHADEMHOSSEINI, ALI · 2017 to 2022
$2.4M
NHLBI NIH HHS R01 HL140618NIBIB NIH HHS R01 EB023052
6 · The paper itself

Abstract

Topical instillation of eye drops remains the most common and easiest route of ocular drug administration, representing the treatment of choice for many ocular diseases. Nevertheless, low ocular bioavailability of topically applied drug molecules can considerably limit their efficacy. Over the last several decades, numerous drug delivery systems (DDS) have been developed in order to improve drug bioavailability on the ocular surfaces. This review systematically covers the most recent advances of DDS applicable by topical instillation, that have shown better performance in in vivo models compared to standard eye drop formulations. These delivery systems are based on in situ forming gels, nanoparticles and combinations of both. Most of the DDS have been developed using natural or synthetic polymers. Polymers offer many advantageous properties for designing advanced DDS including biocompatibility, gelation properties and/or mucoadhesiveness. However, despite the high number of studies published over the last decade, there are several limitations for clinical translation of DDS. This review article focuses on the recent advances for the development of ocular drug delivery systems. In addtion, the potential challenges for commercialization of new DDS are presented.

Indexed as

Drug Delivery SystemsNanoparticlesAdministration, OphthalmicBiological AvailabilityEyeOphthalmic SolutionsOphthalmic SolutionsEye dropGelMicroparticleNanoparticleOcular drug deliveryOcular surface

Identifiers

PMID32027938
PMCPMC7170772
OpenAlexW3004456848

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.